On August 19, 2024, Rashmi Kumar, Director at Myriad Genetics Inc (NASDAQ:MYGN), sold 7,500 shares of the company. The transaction was filed through an SEC filing on the same day. Following this sale, the insider now owns 77,392 shares of Myriad Genetics Inc.
Myriad Genetics Inc., a leader in molecular diagnostics and precision medicine, is focused on transforming patient care through novel molecular diagnostic tests to assess individual disease risk, guide treatment decisions, and evaluate the risk of disease progression and recurrence.
Over the past year, the insider has sold a total of 7,500 shares and made no purchases. This latest transaction is part of a broader trend seen within the company. Over the past year, there have been six insider sales and no insider purchases.
Myriad Genetics Inc.’s share price was $28.01 on the day of sale. The company currently has a market capitalization of around $2.51 billion. According to GF Value, the intrinsic value of the stock is estimated at $23.37, which means the stock is slightly overvalued with a Price to GF Value ratio of 1.2.
The GF value is calculated based on historical multiples such as price-to-earnings ratio, price-to-sales ratio, price-to-book ratio and price-to-free cash flow, together with a GuruFocus adjustment factor based on past earnings and growth as well as Morningstar analysts’ estimates of future business performance.
This insider sale may be of interest to investors who follow insider behavior as an indicator of the company’s future performance and stock valuation.
This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.
This article first appeared on GuruFocus.
